Mekonos is disrupting how drugs are delivered to patients, leading the charge with highly-potent gene therapy approaches. Custom-developed silicon chips, each holding thousands of individually moving nano-needles, are used to carry drug cargo that can be injected into the nucleus of cells, improving uptake and reducing waste.

The initial concept originated from a PhD project at Canterbury University. It quickly became clear that the company needed to be in the US, where major innovations in gene therapy are being developed. Our support has allowed Mekonos to grow, finding success with major pharmaceutical companies as it moves past the seed stage.